Cambridge, MA, USA & Rostock/Berlin, Germany, March 18, 2020 (GLOBAL NEWSWIRE) – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that it will commence testing for the novel coronavirus, or COVID-19. Testing for the virus is part of the Company’s initiative to help local, national and international authorities in their efforts to diagnose cases of COVID-19. Initially, the Company will provide testing for the Mecklenburg-Western Pomerania region and the Company expects to expand testing activities to additional geographical areas within the upcoming weeks.
Prof. Dr. Arndt Rolfs, CEO of the Company, stated, “In the midst of the COVID-19 pandemic, CENTOGENE is maintaining its commitment to our patients, employees and the global community. This means using our advanced technical equipment and broad expert medical knowledge to support our communities to prevent a further spread of the virus and help individuals who may not otherwise have access to testing.”
###
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data and innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 2.1 billion weighted data points from approximately 500,000 patients representing over 120 different countries as of December 31, 2019, or an average of approximately 600 data points per patient.
The Company’s platform includes epidemiologic, phenotypic and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of December 31, 2019, the Company collaborated with over 35 pharmaceutical partners for over 40 different rare diseases.
